Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Nephrology | Urology
Disease Category: Nocturia
Location: United States, IN

Clinical Trial Details

Overview

Research Study Summary

A randomized, double, placebo-controlled, parallel group study to investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia.

Purpose

SER120 will be administered intra-nasally as a single spray in either the left or right nostril each night before bedtime. The placebo will also be administered this same way.

Inclusions

  • Male or female > 50 years of age
  • Documented nocturia > 2 nocturic episodes/night for at least 6 months by history

Exclusions:

  • Obstructive sleep apnea
  • Evidence of current UTI, bladder stone, bladder pain syndrome, or I.C.
  • History of urinary bladder surgery or radiotherapy within the last 24 months prior to enrollment
  • Severe daytime LUTS secondary to benign prostatic hypertrophy, OAB, or severe stress urinary incontinence

To Learn more
Gender

Both Male and Female

Age

50 and up

Overall Status

Recruiting

Facility Type

N/A

Contact

Debbie Johnson, CCRC, Director of Research
First Urology, PSC
101 Hospital Blvd.
Jeffersonville, IN 47130
Phone: (812) 206-8161
Fax: (812) 288-2612

View Map

Research Center Information: First Urology, PSC

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 178191

Date Last Changed: May 2, 2014


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.